HOME >> MEDICINE >> NEWS
Acrux completes enrollment in key phase 2 trial

Melbourne, Australia, 2 May 2007: Drug delivery company Acrux (ASX: ACR), announced today that it has successfully completed enrolment of 40 patients in the final Phase 2 trial of its unique testosterone lotion for treatment of testosterone deficiency in men. Preliminary results of the trial are expected to be available in July 2007.

The trial is being conducted at 8 clinics in the USA. The aim is to demonstrate that discreet daily application of Acrux's user-friendly lotion to the armpits raises the level of testosterone into the normal range. This is being undertaken by measuring testosterone levels in the blood and does not require the measurement of clinical symptoms.

A Phase 3 trial in 150-200 patients will be required before marketing applications can be made to regulatory authorities. This trial is expected to commence in early 2008 and will again require the measurement of testosterone levels in the blood, rather than the impact on clinical symptoms.

Acrux CEO Richard Treagus commented "Our Phase 2 study will complete on time and the remaining requirements to get this compelling product on the market are relatively straightforward. Confidence in the value of our Testosterone MD-Lotion has been further boosted by the interest shown in this product by potential licensing partners."

About Acrux's Testosterone MD-Lotion

Market research in the USA amongst both patients and prescribers that use current testosterone replacement products, including gels and injections, showed a strong preference by the patients for daily application of Acrux's lotion over the existing products. The Acrux product will apply a precise dose of quick-drying lotion to the armpit once daily, via a convenient and ergonomic "no-touch" applicator.

The leading gel is applied each day as a 5 gram dose by hand to the shoulders, upper arms and/or abdomen. It takes longer to dry and patients are advised
'"/>

Contact: Richard Treagus
richard.treagus@acrux.com.au
61-417-520-509
Research Australia
1-May-2007


Page: 1 2

Related medicine news :

1. Acrux and Oreganon further expand their collaboration
2. Acrux granted first grant in Europe, triggering payment from Lilly
3. Acrux patent portfolio advances in USA
4. Acrux acquires rights to commercialise worlds first contraceptive spray
5. Four new us patents granted to Acrux for transdermal drug delivery
6. Acrux reports progress in development of Testosterone MD-Lotion(R) for men
7. Asthmatx completes enrollment in pivotal study of bronchial thermoplasty
8. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
9. GroPep completes final milestone of the path malaria vaccine initiative
10. Im a Kid Too project completes first phase
11. Worlds largest respiratory health study launches next phase

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... 2020 , ... Medisend College of Biomedical Engineering Technology, a ... that prepares graduates for professional careers as field service engineers and biomedical equipment ... , Ms. Williams currently serves as Associate Vice Chancellor of Workforce and Community ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... the Inland Empire’s premier residential addiction treatment center, proudly announces that it has ... includes special preparation for recovery in a world affected by Covid-19. , When ...
(Date:6/28/2020)... ... June 27, 2020 , ... The secret of surviving a pandemic ... rolls of toilet paper. Yet, it was the first product to disappear off the ... The more you have stockpiled, the less need to venture out, the longer you ...
(Date:6/28/2020)... MILWAUKEE (PRWEB) , ... June 28, 2020 , ... ... allergy/immunology societies around the world, dedicates World Allergy Week, from June 28 to ... pandemic caused by SARS CoV-2. , COVID-19, short for “coronavirus disease 2019”, is ...
(Date:6/25/2020)... ... 2020 , ... Denials Management, Inc. has just published The Health Insurance Appeals ... for denials of mental health and substance use disorder (MH/SUD) treatment services. It was ... and explain the steps in the appeals process. Complimentary copies of the Guide ...
Breaking Medicine News(10 mins):
(Date:6/19/2020)... ... 19, 2020 , ... With the success of Burnsville, Fargo, Eden Prairie, Blaine ... Creek. Since the foundation of the Conquer Ninja Gyms in 2015, countless people have ... locations still share the vision of Jake Marshman, who is an avid supporter and ...
(Date:6/19/2020)... YORK (PRWEB) , ... June ... ... the launch of its cross-platform campaign 'Clinical Trials.' This campaign showcases the ... participate in these studies, thereby advancing knowledge and disease treatment. This public ...
(Date:6/19/2020)... ... June 19, 2020 , ... ... American Healthcare Staffing Association (AHSA), a pioneer and leader in healthcare workforce solutions, ... Catholic health systems in the United States. AHTG and AHSA are part of ...
Breaking Medicine Technology:
Cached News: